NOBLEOAK LIFE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.61 AUD | 0.00% |
|
+2.55% | -3.01% |
| Feb. 28 | NobleOak Life Shares Add 7% Despite 55% Plunge in Fiscal H1 Profit | MT |
| Feb. 28 | Transcript : NobleOak Life Limited, H1 2024 Earnings Call, Feb 28, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 10.91 for the current year.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company sustains low margins.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -3.01% | 91.42M | - | ||
| +8.89% | 100B | B- | ||
| +4.09% | 98.18B | B | ||
| -7.71% | 87.73B | B+ | ||
| +9.25% | 70.46B | D+ | ||
| +11.44% | 31.46B | B | ||
| +19.57% | 28.36B | B | ||
| +7.87% | 28.08B | A | ||
| -0.67% | 17.12B | C+ | ||
| -16.27% | 14.19B | B |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NOL Stock
- Ratings NobleOak Life Limited